By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



Meibergdreef 61

  Amsterdam  1105 BA  Netherlands
Phone: 31-20-566-7394 Fax: 31-20-566-9272



Company News
uniQure (QURE) Announces The Successful Development And Scale-Up Of Manufacturing Processes For Its Hemophilia B Gene Therapy Program 7/21/2017 10:21:37 AM
uniQure (QURE) Expands Intellectual Property Portfolio With Newly Issued Patent Providing Broad Protection Of Insect Cell-Based AAV Manufacturing 7/18/2017 11:06:38 AM
uniQure (QURE) Presents New Clinical Data In Hemophilia B Patients Demonstrating Therapeutic Efficacy Of AAV5 Gene Therapy In The Presence Of Pre-Existing Neutralizing Antibodies 7/11/2017 10:47:12 AM
uniQure (QURE) Announces Clinical Data Presentations At The Upcoming International Society On Thrombosis And Hemostasis (ISTH) Congress 6/23/2017 8:35:42 AM
uniQure (QURE) Publishes Data Further Demonstrating Favorable Immunogenicity Profile And Broad Utilization Of AAV5-Based Gene Therapies 6/15/2017 11:10:19 AM
uniQure (QURE) Presents New Data Demonstrating Successful And Effective Transduction Of AAV5 Vector In The Presence Of Pre-Existing Neutralizing Antibodies In Non-Human Primates 5/10/2017 10:48:03 AM
uniQure (QURE) Announces First Quarter 2017 Financial Results And Highlights Recent Company Progress 5/9/2017 10:46:05 AM
uniQure (QURE) Presents New Preclinical Data On AMT-130 In Huntington’s Disease At CHDI’s 12th Annual Huntington’s Disease Therapeutics Conference 4/26/2017 10:45:21 AM
uniQure (QURE) Receives EMA Priority Medicines (PRIME) Designation For AMT-060 In Hemophilia B 4/25/2017 9:01:25 AM
uniQure (QURE) Announces It Will Not Seek Marketing Authorization Renewal For Glybera In Europe 4/20/2017 8:57:58 AM